Erratum: Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: Results from the ESCAPE study (CNS Drugs DOI: 10.1007/s40263-012-0003-4);Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: Results from the ESCAPE study

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 975-982

  Bervoets, Chris ^a   Morrens, Manuel ^a,b   Vansteelandt, Kristof ^c   Kok, Frank ^d   De Patoul, Annick ^e   Halkin, Veronique ^e   Pitsi, Didier ^e   Constant, Eric ^f   Peuskens, Joseph ^c   Sabbe, Bernard ^a,g  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Psychiatric Centre Broeders Alexianen   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MSOURCE   (Netherlands)

^e BRISTOL MYERS SQUIBB   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Psychiatric Hospital Sint Norbertus   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PROLACTIN; RISPERIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CORRELATION ANALYSIS; DRUG EFFICACY; DSM-IV-TR; FEMALE; HUMAN; HUMAN RELATION; LONG TERM MEMORY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RECALL; SCHIZOPHRENIA; SCORING SYSTEM; SEMANTICS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; VERBAL FLUENCY; VERBAL MEMORY; WEIGHT GAIN;

EID: 84873476009     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0011-4     Document Type: Erratum

References (25)

1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
2. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-84.
3. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-47.
4. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41-51.
5. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007;89(1-3):211-24.
6. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-9.
7. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002;441:137-40.
8. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004;483:45-53.
9. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-71.
10. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6:325-37.
11. Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs. 2012;26(2):155-83.
12. Riedel M, Spellmann I, Schennach-Wolff R, et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry. 2010;43(2):50-7.
13. Kim CY, Chung S, Lee JN. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2009;24(4):181-8.
14. Peuskens J, Bervoets C, Kok F, et al. A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia. Eur Psychiatry. Epub 2011 Sept 13.
15. Vaskinn A, Sundet K, Friis S. Can learning potential in schizophrenia be assessed with the standard CVLT-II? An exploratory study. Scand J Psychol. 2008;49(2):179-86.
16. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;16:310-7.
17. Wolfinger R, Chang M. Comparing the SAS GLM and MIXED procedures for repeated measures. Cary: SAS Institute Inc.; 1998.
18. Russell D, Wolfinger R. Fitting nonlinear mixed models with the new NLMIXED procedure: repeated measures. Cary: SAS Institute Inc.; 1997.
19. Keselman HJ, Algina J, Rhonda K, et al. A comparison of two approaches for selecting covariance structures in the analysis of repeated measurements. Commun Stat Simul Comput. 1998;27:591-604.
20. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry. 1996;153:321-30.
21. Bozikas VP, Kosmidis MH, Peltekis A, et al. Sex differences in neuropsychological functioning among schizophrenia patients. Aust N Z J Psychiatry. 2010;44(4):333-41.
22. Wobrock T, Köhler J, Klein P, et al. Achieving symptomatic remission in out-patients with schizophrenia: a naturalistic study with quetiapine. Acta Psychiatr Scand. 2009;120(2):120-8.
23. Popolo R, Vinci G, Balbi A. Cognitive function, social functioning and quality of life in first-episode psychosis: a 1-year longitudinal study. Int J Psychiatry Clin Pract. 2010;14:33-40.
24. Harvey PD, Hassman H, Mao L, et al. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 2007;68(8):1186-94.
25. Mohamed S, Rosenheck R, Swartz M, et al. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry. 2008;165:978-87.